Online inquiry

IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7292MR)

This product GTTS-WQ7292MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CSF1R gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001288705.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1436
UniProt ID P07333
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ7292MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ8116MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ10298MR IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA LGT209
GTTS-WQ3319MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ASN-100
GTTS-WQ12456MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA NKTR-214
GTTS-WQ4422MR IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-663513
GTTS-WQ12188MR IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MORAb-022
GTTS-WQ6302MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CS-1008
GTTS-WQ6894MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA E-6011
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW